Loading...
XASEIBIO
Market cap21mUSD
Dec 23, Last price  
2.36USD
1D
-4.84%
1Q
28.96%
Jan 2017
-98.81%
IPO
-99.86%
Name

Ibio Inc

Chart & Performance

D1W1MN
XASE:IBIO chart
P/E
—
P/S
95.97
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
151.79%
Rev. gr., 5y
-35.52%
Revenues
225k
896,273987,0581,176,6040520,0801,277,3451,007,000205,0001,851,000948,000394,000444,0002,018,0001,638,0002,371,0002,383,0000225,000
Net income
-25m
L-15.03%
-1,666,034-1,869,295-1,907,296-6,078,020-12,142,451-5,675,838-6,198,000-3,666,000-6,625,000-9,764,000-14,532,000-16,105,000-17,593,000-18,915,000-23,259,000-51,005,000-29,311,000-24,907,000
CFO
-19m
L-39.04%
-849,378-1,149,451-2,024,807-2,348,223-5,338,188-6,009,646-4,849,000-4,116,000-4,725,000-8,072,000-13,163,000-13,480,000-13,975,000-13,345,000-30,064,000-37,480,000-30,436,000-18,554,000
Earnings
Feb 07, 2025

Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
URL
https://www.ibioinc.com/
IPO date
Aug 18, 2008
Employees
105
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
225
 
2,383
0.51%
Cost of revenue
16,859
30,449
52,073
Unusual Expense (Income)
NOPBT
(16,634)
(30,449)
(49,690)
NOPBT Margin
Operating Taxes
(1,639)
701
Tax Rate
NOPAT
(16,634)
(28,810)
(50,391)
Net income
(24,907)
-15.03%
(29,311)
-42.53%
(51,005)
119.29%
Dividends
Dividend yield
Proceeds from repurchase of equity
25,516
11,448
77
BB yield
-315.66%
-153.26%
-0.13%
Debt
Debt current
953
13,598
22,308
Long-term debt
6,983
7,613
11,117
Deferred revenue
Other long-term liabilities
63
768
Net debt
(6,274)
14,951
(7,723)
Cash flow
Cash from operating activities
(18,554)
(30,436)
(37,480)
CAPEX
(210)
(5,738)
(11,630)
Cash from investing activities
906
7,009
(5,127)
Cash from financing activities
24,494
2,301
(6,125)
FCF
15,683
(23,954)
(57,252)
Balance
Cash
14,210
4,301
33,521
Long term investments
1,959
7,627
Excess cash
14,199
6,260
41,029
Stockholders' equity
(313,838)
(288,920)
(224,134)
Invested Capital
339,685
317,949
315,128
ROIC
ROCE
EV
Common stock shares outstanding
3,831
612
436
Price
2.11
-82.70%
12.20
-90.76%
132.00
-82.52%
Market cap
8,083
8.22%
7,469
-87.02%
57,559
-80.51%
EV
1,809
22,420
49,836
EBITDA
(15,384)
(29,069)
(45,899)
EV/EBITDA
Interest
172
1,412
Interest/NOPBT